Clinical Trials in New York

Showing 19341-19360 of 22,668 trials

Safety and Efficacy of the Luxe Device to Treat Facial Wrinkles and Rosacea

NCT01618864

This study is designed to evaluate the efficacy and safety of the Luxe™ device for use in wrinkle and rosacea treatment. Up to 60 subjects will treat their periorbital and cheek areas daily for 4 weeks and then twice a week for an additional 4 weeks. Evaluations of improvement will be conducted at the clinic after enrollment and during the treatment at 1, 2, 4, and 8 weeks after initiation.

RosaceaWrinkles

Syneron Medical23 participantsStarted Mar 2012

New York, New York, United States • New York, New York, United States

COMPLETEDNA< 1 mile

Evaluation of the Zilver PTX Drug-Eluting Stent in the Above-the-Knee Femoropopliteal Artery

NCT00120406

The Zilver® PTX™ Drug Eluting Vascular Stent is indicated for the treatment of symptomatic vascular disease of the above-the-knee femoropopliteal artery (ranging from 4 mm to 9 mm in reference vessel diameter) for lesions up to 7 cm long. The clinical trial is stratified by lesion length. The trial will be conducted in 2 phases, with Phase 1 enrolling patients with lesions less than 7 cm long. Phase 2 of the trial will include longer lesions (up to 14 cm long) and will be initiated upon approval by the Food and Drug Administration (FDA).

Peripheral Vascular Diseases

Cook Group Incorporated474 participantsStarted Mar 2005

Mountain View, California, United States • Oceanside, California, United States • Stanford, California, United States +49 more locations

Safety and Efficacy of the Luxe Device to Treat Facial Wrinkles and Rosacea

Evaluation of the Zilver PTX Drug-Eluting Stent in the Above-the-Knee Femoropopliteal Artery

Find Trials by Condition in New York

Study of Silodosin to Facilitate Passage of Urinary Stones

Docetaxel in Treating Children With Relapsed or Refractory Acute Lymphoblastic or Acute Myeloid Leukemia

A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)

Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer

Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma

Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma

A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)

A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe Depression

Gene Testing to Help in the Diagnosis and Treatment of Childhood Brain Tumors

The AttenueX IntraVesical System for the Treatment of Female Stress Urinary Incontinence

Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients

ADenosine Vasodilator Independent Stenosis Evaluation II - ADVISE II

Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma

NP2 Enkephalin For Treatment of Intractable Cancer Pain

An Extension to Study MA21573, Evaluating Tocilizumab in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biological DMARDs and/or Anti-tumor Necrosis Factor (TNF) Therapy

A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema

A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema

Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo